Delta-beta-thalassemia

Delta-beta-thalassemia (also known as δβ-thalassemia) is an inherited hemoglobin disorder characterized by reduced or absent production of both delta (δ) and beta (β) globin chains. It belongs to the broader group of thalassemia syndromes and is caused by large deletions within the beta-globin gene cluster on chromosome 11p15.4, which remove both the delta- and beta-globin genes. The condition primarily affects the hematologic system, leading to an imbalance in globin chain synthesis and resulting in ineffective erythropoiesis and varying degrees of anemia. Individuals who are heterozygous (carriers) for delta-beta-thalassemia typically present with a mild clinical phenotype resembling thalassemia intermedia or thalassemia minor. Key features include mild microcytic hypochromic anemia, elevated levels of fetal hemoglobin (HbF, typically 5–20%), and low or absent hemoglobin A2 (HbA2). Homozygous individuals produce only hemoglobin F and may present with a clinical picture similar to thalassemia intermedia, with moderate anemia, mild splenomegaly, and occasional jaundice. The elevated HbF in homozygotes often provides a compensatory effect, resulting in a milder phenotype compared to homozygous beta-thalassemia major. Management depends on clinical severity. Heterozygous carriers generally require no treatment beyond genetic counseling. Homozygous patients may need intermittent red blood cell transfusions during periods of physiologic stress, infection, or pregnancy. Folic acid supplementation is commonly recommended. In rare cases with more severe anemia, regular transfusion therapy and iron chelation may be necessary. Genetic counseling is important, particularly when a delta-beta-thalassemia carrier partners with a beta-thalassemia carrier, as compound heterozygosity can result in a more severe thalassemia phenotype.

Common questions about Delta-beta-thalassemia